Physician profile
Chandra Marshall
NPI 1922495175
$5,436.92
in general payments reported to CMS, 2019-2025
52 companies · $953 in 2025
The $953 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $303 · 2021: $850 · 2022: $889 · 2023: $1,204 · 2024: $809 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,390.45 | 2020-2025 | |
| Novo Nordisk INC | $907.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $235.21 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.57 | 2023-2025 | |
| Pfizer INC. | $213.48 | 2021-2025 | |
| Lilly USA, LLC | $212.00 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $206.90 | 2019-2025 | |
| Eisai INC. | $176.98 | 2020-2022 | |
| Gilead Sciences, INC. | $172.92 | 2019-2025 | |
| Edwards Lifesciences Corporation | $155.71 | 2022 | |
| Amgen INC. | $128.08 | 2019-2025 | Evenity, Prolia |
| Ibsa Pharma INC. | $90.02 | 2019-2025 | Tirosint, Tirosint, Licart |
| Viiv Healthcare Company | $87.47 | 2024-2025 | Dovato, Apretude |
| Allergan, INC. | $68.29 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.29 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.